Skip to main content

SOP on Protocol Training for Investigators and Study Staff

 Title: Protocol Training for Investigators and Study Staff


Introduction and Purpose:

The purpose of this Standard Operating Procedure (SOP) is to establish the requirements for the conduct of interventional clinical trials within the clinical site. It may also serve as guidance for other types of clinical research studies to ensure adherence to Good Clinical Practice standards and maintain research quality.

Scope:

Before commencing clinical research, the Principal Investigator (PI), sub-investigators, and study staff must undergo training in various aspects, including the protection of human research participants, the handling of personal health information, Good Clinical Practice (GCP) guidelines, Conflict of Interest (COI) principles, and, when applicable, Biosafety Training.

Furthermore, the PI and all study personnel must receive specific study/protocol training to ensure:

  • Compliance with the investigational plan.
  • Protection of the rights, safety, and welfare of study participants.
  • Validity and integrity of study results.

Protocol training is mandatory for interventional clinical trials, encompassing industry-sponsored trials, network trials, institutional trials, and investigator-initiated trials. While the PI holds overall responsibility for clinical trial conduct, certain tasks or responsibilities may be delegated to sub-investigators, clinical research coordinators, study coordinators, data coordinators, or other study personnel. Adequate training must be completed before these individuals participate in the clinical trial.

Definitions and Acronyms:

  • Clinical Research: All research involving human participants, excluding secondary studies using existing biological specimens or publicly available data.
  • Clinical Trial: Clinical research studies involving human participants assigned to an intervention aimed at evaluating its impact on health-related biomedical or behavioral outcomes.
  • CFR: Code of Federal Regulations
  • GCP: Good Clinical Practices
  • HIPAA: Health Insurance Portability and Accountability Act
  • ICH: International Council on Harmonization
  • IDS: Investigational Drug Services
  • IRB: Institutional Review Board
  • PI: Principal Investigator
  • SIV: Site Initiation Visit
  • SOP: Standard Operating Procedure

Procedure:

Initial Protocol Training:

  • Initial protocol-specific training is typically conducted by the sponsor, sponsor representative, or delegated trainer during a Site Initiation Visit (SIV) or initial training meeting, excluding self-training.
  • Training covers the purpose of the research, protocol design, investigational product details, task-specific skills, regulatory requirements, and research conduct standards.
  • For investigator-initiated trials, the PI conducts initial protocol-specific training after IRB approval and before any study-related research procedures commence.
  • Study personnel who miss the SIV or initial training must complete training before conducting study-related research procedures.
  • Protocol training must be documented, with all participating study personnel signing a protocol training log, indicating the trainee and trainer names, training date, and content details including the protocol version.

Investigational Drug Services (IDS):

  • For clinical trials involving investigational drugs and utilizing the IDS pharmacy, the lead pharmacist attends the investigational drug/pharmacy segment of the SIV.
  • The lead pharmacist provides training to other pharmacists and technicians involved in the study.
  • IDS pharmacy personnel maintain separate protocol training records.

Specialized Groups:

  • Specialized groups with study-specific roles and tasks may assign individuals to attend the SIV or protocol training.
  • A representative from the group may receive initial training at the SIV and subsequently train other group members before their participation in the study.
  • For in-patient clinical trials or studies with in-patient components, clinic Nurse Managers or Nurse Educators attend the SIV to ensure clinic nursing staff receive training on the study treatment plan and monitoring parameters.
  • Routine job procedure performers receive training within their department and are not required to undergo study-specific training.

Ongoing and Continuing Protocol Training:

  • The PI and study personnel should hold routine meetings throughout the clinical trial to provide protocol refresher training as needed and review study progress, subject enrollment, adverse events, deviations, monitoring results, and assignment of responsibilities.
  • Meeting summaries should include date, attendance, agenda, and follow-up tasks. Meeting notes must be maintained and made available for review upon request.
  • Protocol amendments may necessitate additional training depending on the extent and nature of the changes.
  • Notification of protocol amendments is sent to the PI and all sub-investigators, coordinators, and study staff listed on the IRB application.
  • Administrative changes in a protocol amendment, such as minor errors or non-operational modifications, do not require re-training.
  • Protocol amendments affecting operational aspects of the study require re-training.
  • Additional protocol training following an amendment may be led by the sponsor or overseen by the PI, either in a formal meeting or through individual protocol review. Documentation of this training should be kept.
  • Electronic confirmation of individual review completion may serve as documentation.

Maintenance of Training Records:

  • Protocol-specific training records for the PI, sub-investigators, and study personnel must be kept with the study records, usually within the Regulatory Binder with other essential documents.
  • Individual training records that are not protocol-specific, such as GCP, HIPAA, CITI, etc., can be maintained separately in an electronic or paper individual training file. These records must be available for review by study monitors or regulatory inspectors upon request.

Materials Required:

  • Protocol Training Log or other protocol-specific training documentation.
  • Current version of the study protocol.
  • Agenda and training materials from the SIV or PI-led training for investigator-initiated clinical trials.
  • Delegation of Authority log.

References:

  • 21 CFR Part 312 Subpart D: Responsibilities of Sponsors and Investigators.
  • ICH Guidance for Industry E6(R2): Good Clinical Practice 1.29, 6.10.
  • FDA Guidance for Industry – Investigator Responsibilities (October 2009).


Document Approval:


Revision History:

Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more